Strategic Maneuvers | Learn about Hologic's growth strategies, including successful smaller acquisitions and strict expense management, aimed at navigating market challenges and tariff-related issues |
Financial Forecasts | Delve into Hologic's FY2025 guidance, including a projected Q4 rebound and analyst price targets ranging from $70 to $85, reflecting diverse market perspectives |
Breast Health Challenges | Explore the complexities in Hologic's breast health segment and its potential for recovery, which could significantly boost overall company performance |
Diagnostic Dominance | Hologic's molecular diagnostics segment shows robust 8% growth, highlighting the company's strength in developing and marketing advanced diagnostic solutions |

Metrics to compare | HOLX | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipHOLXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | 23.9x | −0.4x | |
PEG Ratio | 0.00 | −0.16 | 0.00 | |
Price / Book | 0.0x | 2.0x | 2.6x | |
Price / LTM Sales | 0.0x | 2.6x | 3.1x | |
Upside (Analyst Target) | 0.0% | 137.5% | 49.3% | |
Fair Value Upside | Unlock | 19.1% | 6.7% | Unlock |